Anti-Mouse MAdCAM-1 (MECA-367) – Purified in vivo GOLD^TM Functional Grade

Endothelial Cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody is stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 - 8°C Wet Ice

MECA-367 activity is directed against mouse MAdCAM-1.

MAdCAM-1 is a cell surface glycoprotein selectively expressed on high endothelial venules of mucosal lymphoid organs and Peyer’s patches as well as lamina propria venules.

MAdCAM-1 is a cell adhesion leukocyte receptor expressed by mucosal venules that helps direct lymphocyte traffic into mucosal tissues and regulates the passage and retention of leukocytes^{1, 2}. MAdCAM-1 binds integrin receptor α4β7 and L-selectin^{2, 3, 4}. Two alternatively spliced isoforms of MAdCAM-1 exist⁵, both of which are capable of binding α4β7².

MECA-367 was generated by immunizing Wister rats with endothelial cells isolated from BALB/c mesenteric and peripheral lymph nodes⁶. Immunohistological screening of hybridomas yielded two mAbs, MECA-367 and MECA-89, that stain high endothelial venules (HEVs) in mucosal lymphoid organs and Peyer’s patches, but not peripheral lymph nodes (axillary, brachial, popliteal, and inguinal). Immunofluorescence staining of high endothelial cells shows that both MECA-367 and MECA-89 react with antigens on the cell surface. The epitopes for MECA-367 and MECA-89 are distinct. MECA-367 recognizes the N-terminal immunoglobulin domain of MAdCAM-l, and MECA-89 recognizes the second immunoglobulin domain^{4, 5}.

MECA-367 inhibits the binding of normal and neoplastic lymphocytes to HEVs in mucosa-associated lymphoid organs and Peyer’s patches⁶. In contrast, MECA-89 reacts with the same vessels, binds to isolated MECA-367 antigen, but has no effect on lymphocyte binding. In vivo, MECA-367 blocks homing of normal lymphocytes to mucosa-associated lymphoid tissues⁶. MECA-367 also inhibits α4β7 binding³ and blocks sticking and rolling of preactivated lymph node cells⁴.

Integrin a4ß7, CD62L

1. https://www.uniprot.org/uniprotkb/Q61826/entry
2. Schiffer SG, Day E, Latanision SM, et al. Biochem Biophys Res Commun. 216(1):170-176. 1995.
3. Berlin C, Berg EL, Briskin MJ, et al. Cell. 74(1):185-195. 1993.
4. Bargatze RF, Jutila MA, Butcher EC. Immunity. 3(1):99-108. 1995.
5. Briskin MJ, McEvoy LM, Butcher EC. Nature. 363(6428):461-464. 1993.
6. Streeter PR, Berg EL, Rouse BT, et al. Nature. 331(6151):41-46. 1988.
7. Berlin C, Bargatze RF, Campbell JJ, et al. Cell. 80(3):413-422. 1995.
8. Nakache M, Berg EL, Streeter PR, et al. Nature. 337(6203):179-181. 1989.